SEC Filings

Edgewise Books $1.35 Billion Gain On Sevasemten Sale Hours After Servier's Pivotal Trial Fails

Servier's Becker trial missed its goals a day before the filing, and none of the up to $1.1 billion in milestones sits in the gain.

Matteo Parrino Jonathan Ponciano

Matteo Parrino, Jonathan Ponciano

— 2 min read
Share
Edgewise Books $1.35 Billion Gain On Sevasemten Sale Hours After Servier's Pivotal Trial Fails

Edgewise Therapeutics, a heart-disease drug developer that sold off its muscular dystrophy program, booked a $1,348.1 million gain on the sale in its quarterly report on Wednesday, counting none of the up to $1,100.0 million in milestone payments still owed by the buyer. Servier's GRAND CANYON trial of the drug had missed all its endpoints.

Milestones left out of the gain

Edgewise sold sevasemten to Servier, and the deal closed on July 10, 2026. It received $1,396.1 million in cash up front, and another $153.9 million went into escrow, for expected initial proceeds of $1,550.0 million. Only $3.9 million of the escrowed money was recognized at closing.

Edgewise left every milestone dollar out of the gain, pointing to regulatory and commercial uncertainties beyond its control. The potential payments include $200.0 million, or $100.0 million for a narrower label, on U.S. approval in Becker, $600.0 million on U.S. approval in Duchenne, and $300.0 million if annual U.S. net sales top $550.0 million. Edgewise says Servier controls those outcomes and it may receive none of them.

Servier is analyzing the study results and prior clinical data. The company's risk factors say the miss could prevent one or more milestones from being reached.

The gain also includes a receivable tied to the indemnification Edgewise gave the buyers. The company is weighing resolution options and will reassess what it can recover at each reporting date.

Profit, tax bill and cash pile

Net income was $1,166.2 million for the third quarter, against a $40.7 million loss a year earlier, or $10.71 per basic share. Diluted earnings were $9.65 per share. The company says that figure is not a guide to future performance because it includes the gain.

Income tax expense came to $155.3 million, with $108.9 million still accrued as taxes at quarter-end. Edgewise also has a remaining $40.0 million commitment through January 2027 to buy federal tax credits. The prior quarterly report had said only that it expected a gain.

Cash, cash equivalents and marketable securities reached $1,743.9 million, up from $530.1 million at the end of 2025. The company says that funds operations for at least 12 months.

A heart company now

Before the sale, Edgewise's lead program was a muscular dystrophy drug. It now describes itself as a clinical-stage company focused on cardiovascular disease. Its lead candidate, EDG-7500, treats hypertrophic cardiomyopathy, and the company said it expects to start a Phase 3 trial by year-end 2026. It has also dosed the first patient in a Phase 2 trial of EDG-15400 in heart failure with preserved ejection fraction.

The company's market value was $4.1 billion in Wednesday trading.

Edgewise says it will revisit its milestone and indemnity conclusions at each reporting date as Servier completes its analysis of the failed trial.

Sources

Read more